Ifinatamab deruxtecan
- Generic Name
- Ifinatamab deruxtecan
- Drug Type
- Biotech
- CAS Number
- 2484870-92-8
- Unique Ingredient Identifier
- C6I0GC0GX5
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Conditions
- Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1440
- Registration Number
- NCT06925737
- Locations
- 🇺🇸
Cancer and Hematology Centers of Western Michigan ( Site 0015), Grand Rapids, Michigan, United States
🇺🇸St. Vincent Frontier Cancer Center-Research ( Site 0037), Billings, Montana, United States
🇺🇸Blue Ridge Cancer Care ( Site 0024), Roanoke, Virginia, United States
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Conditions
- Castration-Resistant Prostatic CancerMetastasis
- Interventions
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT06863272
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 209
- Registration Number
- NCT06780111
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Conditions
- Lung Neoplasm
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 144
- Registration Number
- NCT06780098
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 96
- Registration Number
- NCT06780085
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 510
- Registration Number
- NCT06644781
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-ku, Japan
🇯🇵Keio University Hospital, Shinjuku-ku, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Japan
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 123
- Registration Number
- NCT06362252
- Locations
- 🇺🇸
University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 520
- Registration Number
- NCT06330064
- Locations
- 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Pih Health Hematology Medical Oncology, Whittier, California, United States
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 540
- Registration Number
- NCT06203210
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Clinical Research Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA Hematology-Oncology, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.